2:59PM
Glycogenesis announced the publication of an article about the co's cancer drug candidate GCS-100 (GLGS) 1.09 +0.08:Co announced the publication of an in-depth article (in the American Association of Cancer Researcher's publication Cancer Research, Sept 15, 2005; Vol. 65, No.18 edition) introducing new in vitro findings about the co's cancer drug candidate GCS-100. The paper concludes that "Collectively, these findings provide the frame work for clinical trials of GCS-100, either alone or in combination with dexamethasone, to enhance clinical efficacy, reduce toxicity, and overcome drug resistance to conventional and Velcade therapy in patients with relapsed/refractory multiple myeloma."
Info kam vor wenigen Minuten...
bigcharts.marketwatch.com/charts/...gs=1&rand=5393&mocktick=1" style="max-width:560px" >
Bin soeben klein und spekulativ zu $ 1,07 eingestiegen.
Warum? Volumen und Kurs ziehen heftig an... falls die $1 Marke hält, bleib ich dabei.
Grüße
Glycogenesis announced the publication of an article about the co's cancer drug candidate GCS-100 (GLGS) 1.09 +0.08:Co announced the publication of an in-depth article (in the American Association of Cancer Researcher's publication Cancer Research, Sept 15, 2005; Vol. 65, No.18 edition) introducing new in vitro findings about the co's cancer drug candidate GCS-100. The paper concludes that "Collectively, these findings provide the frame work for clinical trials of GCS-100, either alone or in combination with dexamethasone, to enhance clinical efficacy, reduce toxicity, and overcome drug resistance to conventional and Velcade therapy in patients with relapsed/refractory multiple myeloma."
Info kam vor wenigen Minuten...
Bin soeben klein und spekulativ zu $ 1,07 eingestiegen.
Warum? Volumen und Kurs ziehen heftig an... falls die $1 Marke hält, bleib ich dabei.
Grüße
Werbung
